FDA Peptide Reclassification 2026: What It Means for Providers When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions The FDA has issued clear signals on BPC 157: it is not approved for human use in any form due to potential significant safety risks. This critical classification profoundly impacts research and Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives Compounded "semaglutide" is not FDA approved semaglutide.com FDA May Reverse Ban on 14 PeptidesWhat It Means for Your Beauty Routine Allure